Literature DB >> 12208865

An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis.

Anindita Bhoumik1, Tian-Gui Huang, Vladimir Ivanov, Lisa Gangi, Rui F Qiao, Savio L C Woo, Shu-Hsia Chen, Ze'ev Ronai.   

Abstract

Melanomas are among the aggressive tumor types because of their notorious resistance to treatment and their high capacity to metastasize. ATF2 is among transcription factors implicated in the progression of melanoma and its resistance to treatment. Here we demonstrate that the expression of a peptide spanning amino acids 50-100 of ATF2 (ATF2(50-100)) reduces ATF2 transcriptional activities while increasing the expression and activity of c-Jun. Altering the balance of Jun/ATF2 transcriptional activities sensitized melanoma cells to apoptosis, an effect that could be attenuated by inhibiting c-Jun. Inhibition of ATF2 via RNA interference likewise increased c-Jun expression and primed melanoma cells to undergo apoptosis. Growth and metastasis of SW1 and B16F10 mouse melanomas were inhibited by ATF2(50-100) to varying degrees up to a complete regression, depending on the mode (inducible, constitutive, or adenoviral delivery) of its expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208865      PMCID: PMC151112          DOI: 10.1172/JCI16081

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Induction of apoptosis by the transcription factor c-Jun.

Authors:  E Bossy-Wetzel; L Bakiri; M Yaniv
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

2.  Activation of the rat cyclin A promoter by ATF2 and Jun family members and its suppression by ATF4.

Authors:  M Shimizu; Y Nomura; H Suzuki; E Ichikawa; A Takeuchi; M Suzuki; T Nakamura; T Nakajima; K Oda
Journal:  Exp Cell Res       Date:  1998-02-25       Impact factor: 3.905

3.  Autocrine growth and anchorage independence: two complementing Jun-controlled genetic programs of cellular transformation.

Authors:  H van Dam; S Huguier; K Kooistra; J Baguet; E Vial; A J van der Eb; P Herrlich; P Angel; M Castellazzi
Journal:  Genes Dev       Date:  1998-04-15       Impact factor: 11.361

4.  ATF2 confers radiation resistance to human melanoma cells.

Authors:  Z Ronai; Y M Yang; S Y Fuchs; V Adler; M Sardana; M Herlyn
Journal:  Oncogene       Date:  1998-01-29       Impact factor: 9.867

5.  Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase.

Authors:  S Y Fuchs; L Dolan; R J Davis; Z Ronai
Journal:  Oncogene       Date:  1996-10-03       Impact factor: 9.867

6.  Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation.

Authors:  A Behrens; M Sibilia; E F Wagner
Journal:  Nat Genet       Date:  1999-03       Impact factor: 38.330

7.  CREB and its associated proteins act as survival factors for human melanoma cells.

Authors:  D Jean; M Harbison; D J McConkey; Z Ronai; M Bar-Eli
Journal:  J Biol Chem       Date:  1998-09-18       Impact factor: 5.157

8.  Expression of dominant negative CREB reduces resistance to radiation of human melanoma cells.

Authors:  Y M Yang; L R Dolan; Z Ronai
Journal:  Oncogene       Date:  1996-05-16       Impact factor: 9.867

9.  Transcription factor ATF2 cooperates with v-Jun to promote growth factor-independent proliferation in vitro and tumor formation in vivo.

Authors:  S Huguier; J Baguet; S Perez; H van Dam; M Castellazzi
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

10.  Fas and Fas ligand interactions suppress melanoma lung metastasis.

Authors:  L B Owen-Schaub; K L van Golen; L L Hill; J E Price
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more
  37 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  PKCε promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria.

Authors:  Eric Lau; Harriet Kluger; Tal Varsano; KiYoung Lee; Immo Scheffler; David L Rimm; Trey Ideker; Ze'ev A Ronai
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

3.  Differentially expressed genes between solitary large hepatocellular carcinoma and nodular hepatocellular carcinoma.

Authors:  Lian-Yue Yang; Wei Wang; Ji-Xiang Peng; Jie-Quan Yang; Gen-Wen Huang
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

Review 4.  Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.

Authors:  Marie A Bogoyevitch; Bostjan Kobe
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

Review 5.  ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease.

Authors:  Gregory Watson; Ze'ev A Ronai; Eric Lau
Journal:  Pharmacol Res       Date:  2017-02-15       Impact factor: 7.658

6.  Tumour necrosis factor alpha induces co-ordinated activation of rat GSH synthetic enzymes via nuclear factor kappaB and activator protein-1.

Authors:  Heping Yang; Nathaniel Magilnick; Xiaopeng Ou; Shelly C Lu
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

7.  Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

8.  Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2.

Authors:  Tal Varsano; Eric Lau; Yongmei Feng; Marine Garrido; Loribelle Milan; Susanne Heynen-Genel; Christian A Hassig; Ze'ev A Ronai
Journal:  Clin Cancer Res       Date:  2013-04-15       Impact factor: 12.531

9.  Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.

Authors:  Shilin Yang; Yi Yang; John Raycraft; Hongtao Zhang; Sandra Kanan; Yajun Guo; Ze'ev Ronai; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

10.  Preclinical studies of celastrol and acetyl isogambogic acid in melanoma.

Authors:  Sabiha Abbas; Anindita Bhoumik; Russell Dahl; Stefan Vasile; Stan Krajewski; Nicholas D P Cosford; Ze'ev A Ronai
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.